Kura Oncology
KURA
Kura Oncology (KURA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.77
- EPS estimate
- −$0.88
- EPS surprise
- +12.23%
- Revenue surprise
- +3.53%
- Revenue
- $20.9M
- Revenue estimate
- $20.2M
- Reported
- Aug 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.88 | −$0.77 | +12.23% | $20.9M | SEC |
| Q1 2026 | May 12, 2026 | −$0.83 | −$0.83 | +0.54% | $18.3M | SEC |
| Q4 2025 | Mar 5, 2026 | −$0.64 | −$0.92 | −43.97% | $17.3M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.73 | −$0.85 | −16.44% | $20.8M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.37 | −$0.75 | −104.97% | $15.3M | SEC |
| Q1 2025 | May 1, 2025 | −$0.60 | −$0.66 | −10.02% | $14.1M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.64 | −$0.22 | +65.39% | $53.9M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.63 | −$0.63 | −0.62% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.63 | −$0.59 | +5.77% | $0.00 | SEC |
| Q1 2024 | May 2, 2024 | −$0.55 | −$0.59 | −7.84% | $0.00 | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.55 | −$0.55 | +0.15% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.54 | −$0.50 | +7.44% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.54 | −$0.53 | +2.61% | $0.00 | SEC |
| Q1 2023 | May 10, 2023 | −$0.54 | −$0.50 | +7.05% | $0.00 | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.57 | −$0.49 | +14.34% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.56 | −$0.53 | +5.73% | $0.00 | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.52 | −$0.52 | −0.85% | $0.00 | SEC |
| Q1 2022 | May 4, 2022 | −$0.52 | −$0.49 | +5.19% | $0.00 | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.54 | −$0.49 | +8.41% | $0.00 | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.54 | −$0.50 | +7.17% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Kura Oncology (KURA) last report earnings?
Kura Oncology last reported on Aug 12, 2026, covering fiscal Q2 2026.
Did KURA beat earnings estimates?
Yes. Kura Oncology reported EPS of −$0.77 for Q2 2026 against a −$0.88 estimate — a 12.23% beat.
How much revenue did KURA report last quarter?
Kura Oncology reported $20.9M in revenue for Q2 2026, against a consensus estimate of $20.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.